---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-25-000083"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2025-03-24T23:59:59+00:00"
generated_at: "2026-05-24T06:23:17.581377+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Emergent closes sale of Baltimore-Bayview facility to Syngene for ~$36.5M

## Summary
- Sale closed on March 19, 2025; Emergent received ~$36.5M at closing, subject to post-closing adjustments.
- Syngene acquired assets and equipment of the Baltimore-Bayview drug substance manufacturing site.
- Emergent retains rights to secure manufacturing services and capacity at the facility for future growth and pandemic response.
- CEO Joe Papa says deal streamlines operations while maintaining flexibility; transaction supports multi-year turnaround.

## SEC filing metadata
- accession: 0001367644-25-000083
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2025-03-24T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000083/0001367644-25-000083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000083/ebs-20250319.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-25-000083
- JSON: https://secwatch.observer/filing/0001367644-25-000083.json
- Plain text: https://secwatch.observer/filing/0001367644-25-000083.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.